NewAmsterdam Pharma Warrant
NAMSW
11 hedge funds and large institutions have $9.32M invested in NewAmsterdam Pharma Warrant in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
10% more funds holding
Funds holding: 10 → 11 (+1)
0.03% more ownership
Funds ownership: 1.45% → 1.48% (+0.03%)
19% less capital invested
Capital invested by funds: $11.5M → $9.32M (-$2.17M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$242K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$80.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFM
TFC Financial Management
Boston,
Massachusetts
|
-$29.6K |
| 2 |
HF
HRT Financial
New York
|
-$24.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FLSM
1
Frazier Life Sciences Management
Palo Alto,
California
| $3.5M | – | – | – |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $2.33M | – | – | – |
|
|
AAA
3
Affinity Asset Advisors
New York
| $1.49M | +$80.5K | +10,375 | +5% |
|
|
BCLSI
4
Bain Capital Life Sciences Investors
Boston,
Massachusetts
| $700K | – | – | – |
|
|
DM
5
Deerfield Management
New York
| $650K | – | – | – |
|
|
MIM
6
Monashee Investment Management
Boston,
Massachusetts
| $218K | +$242K | +31,189 | New |
|
|
HF
7
HRT Financial
New York
| $189K | -$24.8K | -3,201 | -11% |
|
|
LCM
8
Laurion Capital Management
New York
| $117K | – | – | – |
|
|
VI
9
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $67K | – | – | – |
|
|
TFM
10
TFC Financial Management
Boston,
Massachusetts
| $43.3K | -$29.6K | -3,819 | -38% |
|
11
CIBC Private Wealth Group
Atlanta,
Georgia
| $7.13K | – | – | – |
|
NAMSW Hedge Fund Activity: Q3 2024 in Review
11 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q3 2024, worth a combined $9.32M — down 19% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NAMSW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $242K. The largest seller was TFC Financial Management, cutting an estimated $29.6K.
- 11 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q3 2024, up from 10 in Q2 2024.
- Funds reported $9.32M of NewAmsterdam Pharma Warrant stock for Q3 2024, down 19% quarter-over-quarter.
- 1 fund opened new NewAmsterdam Pharma Warrant positions in Q3 2024 and 0 closed out, a net change of +1 holder.
- The largest NewAmsterdam Pharma Warrant buyer in Q3 2024 was Monashee Investment Management, an estimated $242K added.
- The largest NewAmsterdam Pharma Warrant seller in Q3 2024 was TFC Financial Management, an estimated $29.6K sold.
Based on aggregated 13F filings for Q3 2024.